Trial Profile
A Phase I, Open-Label Study of GSK3174998 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Subjects With Selected Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs GSK 3174998 (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Acronyms ENGAGE-1
- Sponsors GlaxoSmithKline; GSK
- 03 Jun 2020 Status changed from active, no longer recruiting to completed.
- 05 May 2020 Planned End Date changed from 30 Apr 2020 to 7 May 2020.
- 05 May 2020 Planned primary completion date changed from 30 Apr 2020 to 7 May 2020.